Literature DB >> 2869919

Pharmacologically induced pulmonary vasodilatation in children and young adults with primary pulmonary hypertension.

R J Barst.   

Abstract

To evaluate pulmonary vasoreactivity in children and young adults with primary pulmonary hypertension, we performed cardiac catheterizations on nine patients with primary pulmonary hypertension (nine months to 23 years old) and made hemodynamic measurements: before and after infusing prostacyclin, and before and after administering sublingual nifedipine. Based upon the response to prostacyclin, patients were divided into responders and nonresponders using the following criteria: 20 percent or greater decrease in mean pulmonary arterial pressure; an increase in cardiac index; and no change, or a decrease in the pulmonary vascular resistance to systemic vascular resistance ratio. By these criteria, five of the nine patients had a reactive pulmonary vascular bed and responded to prostacyclin administration. In addition, they all responded to nifedipine. The remaining four did not respond to either drug. There was a close correlation (r = 0.85, p less than 0.01) between the magnitude of the pulmonary vasodilator response to treatment with prostacyclin and nifedipine. There was also a significant inverse correlation between the age of the patient at the time of the study and the pulmonary vasodilator response to administration of prostacyclin (r = 0.91, p less than 0.01) and nifedipine (r = 0.82, p less than 0.01); ie, both drugs produced a greater fall in pulmonary arterial pressure in younger patients with primary pulmonary hypertension than in older ones.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869919     DOI: 10.1378/chest.89.4.497

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  27 in total

Review 1.  Primary pulmonary hypertension in childhood.

Authors:  S G Haworth
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

2.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

Review 3.  Advances in pediatric pulmonary arterial hypertension.

Authors:  Dunbar Ivy
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

Review 4.  Drug treatment of pulmonary hypertension in children.

Authors:  Erika E Vorhies; David Dunbar Ivy
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

5.  Diagnosis and management of primary pulmonary hypertension.

Authors:  U Krishnan
Journal:  Indian J Pediatr       Date:  2000-07       Impact factor: 1.967

6.  Non-congenital heart disease associated pediatric pulmonary arterial hypertension.

Authors:  D D Ivy; J A Feinstein; T Humpl; E B Rosenzweig
Journal:  Prog Pediatr Cardiol       Date:  2009-12-01

7.  Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin.

Authors:  R J Barst
Journal:  Heart       Date:  1997-04       Impact factor: 5.994

Review 8.  Progress in the diagnosis and management of pulmonary hypertension in children.

Authors:  Jeremy Nicolarsen; Dunbar Ivy
Journal:  Curr Opin Pediatr       Date:  2014-10       Impact factor: 2.856

Review 9.  The future potential of eicosanoids and their inhibitors in paediatric practice.

Authors:  T Shimizu
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

10.  Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome.

Authors:  W Budts; N Van Pelt; H Gillyns; M Gewillig; F Van De Werf; S Janssens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.